期刊名称：CANCER COMMUNICATIONS ISSN： 2523-3548 出版频率： Article-by-article 出版社： WILEY, 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774   出版社网址： https://www.biomedcentral.com/ 期刊网址： https://cancercommun.biomedcentral.com/ 影响因子： 10.392 主题范畴： ONCOLOGY;    China Journals 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Aims and scope Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics. Open access All articles published by Cancer Communications are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here. As authors of articles published in Cancer Communications you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement. For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed. Article-processing charges Open access publishing is not without costs. Cancer Communications therefore levies an article-processing charge of £1370.00/$2145.00/€1745.00 for each article accepted for publication. If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page. BioMed Central provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service. Cancer Communications offers waivers to authors for selected high quality articles. For rapid feedback on the potential suitability of an article for waiver, please send a pre-submission enquiry to the editorial office, providing the article title, abstract and a brief cover letter. Indexing services All articles published in Cancer Communications are included in: DOAJ MEDLINE PubMed PubMed Central Science Citation Index Expanded Scopus The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink. Peer-review policy Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here. Cancer Communications operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board. Editorial policies The editorial policies of Cancer Communications are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China. Unless otherwise stipulated in these guidelines, all manuscripts submitted to Cancer Communications should adhere to BioMed Central's editorial policies. Citing articles in Cancer Communications Articles in Cancer Communications should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number. Article citations follow this format: Authors: Title. Cancer Commun [year], [volume number]:[article number]. e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Cancer Commun 2009, 1:115. refers to article 115 from Volume 1 of the journal. Appeals and complaints If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher. Why publish your article in Cancer Communications High visibility Cancer Communications's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.  Speed of publication Cancer Communications offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF. Flexibility Online publication in Cancer Communications gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles). Promotion and press coverage Articles published in Cancer Communications are included in article alerts and regular email updates. Some may be highlighted on Cancer Communications’s pages and on the BioMed Central homepage. In addition, articles published in Cancer Communications may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cancer Communications. A list of articles recently press-released by journals published by BioMed Central is available here. Copyright As an author of an article published in Cancer Communications you retain the copyrightof your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement). For further information about the advantages of publishing in a journal from BioMed Central, please click here. Instructions to Authors Submission guidelines Our 3-step submission process   Before you submit Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit. Make sure you are submitting to the most suitable journal - Aims and scope Understand the costs and funding options - Fees and funding Make sure your manuscript is accurate and readable - Language editing services Understand the copyright agreement - Copyright   Ready to submit To give your manuscript the best chance of publication, follow these policies and formatting guidelines. Cancer Communications publishes the following article types: Original article Review Commentary Research highlight Case report Letter to the Editor News and Views Guideline and Consensus Short report Study protocol Correspondence Click the relevant link to find style and formatting information for the article you are going to submit. General formatting rules for all article types - Preparing your manuscript Make sure your submission is complete - Prepare supporting information Copyright and license agreement - Conditions of publication Read and agree to our Editorial Policies - Editorial policies   Submit and promote After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond. Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.  Who decides whether my work will be accepted? - Peer-review policy Want to submit to a different journal? - Manuscript transfers Spreading the word - Promoting your publication Submit your manuscript in Editorial Manager Editorial Board Honorary Editor-in-Chief  Prof Yi-Xin Zeng, Chinese Academy of Sciences member, China Editor-in-Chief  Prof Rui-Hua Xu, Sun Yat-sen University Cancer Center, China Deputy Editor-in-Chief Prof Peng Huang, Sun Yat-sen University Cancer Center, China Associate Editors  Prof Chao-Nan Qian, Sun Yat-sen University Cancer Center, China Prof Wei Zhang, Wake Forest Baptist Comprehensive Cancer Center, USA Editorial Board  Prof Carlos Arteaga, Vanderbilt University, USA Prof Su-Juan Ba, National Foundation for Cancer Research, USA Prof Mikhail V. Blagosklonny, Roswell Park Cancer Institute, USA     Prof Yi-Hai Cao, Krolinska Institute, Sweden Prof Webster Cavenee, University of California at San Diego, USA Prof Anthony T.C. Chan, The Chinese University of Hong Kong, China  Prof Ke-Xin Chen, Tianjin Medical University, China Prof Wan-Qing Chen, Peking Union Medical College, China Prof Zhe-Sheng Chen, St. John's University, USA Prof Shi-Yuan Cheng, University of Pittsburgh Cancer Institute, USA  Prof Laurence Cooper, University of Texas MD Anderson Cancer Center, USA   Prof Ingemar Ernberg, Karolinska Institute, Sweden   Prof Jian-Hua Fu, Sun Yat-sen University Cancer Center, China  Prof Li-Wu Fu, Sun Yat-sen University Cancer Center, China  Prof Gregory Fuller, University of Texas MD Anderson Cancer Center, USA  Prof Sharlene Gill, BC Cancer Agency Vancouver, Canada  Prof Jie He, Chinese Academy of Medical Sciences, China   Prof Carl-Henrik Heldin, Uppsala University, Sweden   Prof Wen-Lin Huang, Sun Yat-sen University Cancer Center, China   Prof Guido Kroemer, INSERM, France  Prof Sheng-Ping Li, Sun Yat-sen Univeristy Cancer Center, China  Prof Ye-Xiong Li, Peking Union Medical College, China  Prof Dong-Xin Lin, Chinese Academy of Medical Sciences, China  Prof Quertin Liu, Sun Yat-sen University Cancer Center, China  Prof Zhi-Hua Liu, Peking Union Medical College, China  Prof Kwok Wai Lo, The Chinese University of Hong Kong, China  Prof Zhi-Min Lu, University of Texas MD Anderson Cancer Center, USA  Prof Jun Ma, Sun Yat-sen University Cancer Center, China  Prof Jeffrey P MacKeigan, Van Andel Research Institute, USA   Prof Gerry Melino, University of Rome, Italy  Prof Delia Mezzanzanica, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy  Prof Rene-Olivier Mirimanoff, University of Lausanne Medical Center, Switzerland  Prof Boris Pasche, Comprehensive Cancer Center of Wake Forest University, USA  Prof You-Lin Qiao, Peking Union Medical College, China  Prof Neal NR Rosen, Memorial Sloan-Kettering Cancer Center, USA  Prof Keng Shen, Peking Union Medical College, China  Prof Ilya Shmulevich, Institute for Systems Biology, USA  Prof Er-Wei Song, Sun Yat-sen Memorial Hospital, China  Prof Anil K Sood, University of Texas MD Anderson Cancer Center, USA  Prof Qian Tao, The Chinese University of Hong Kong, China  Prof Yun-Guang Tong, UCLA School of Medicine, USA  Prof Joseph Wee, National Cancer Center, Singapore  Prof Xiao-Ming Xie, Sun Yat-sen University Cancer Center, China   Prof Xiang-Xi (Mike) Xu, Sylvester Comprehensive Cancer Center, USA      Prof Li Yan, GlaxoSmithKline PLC, USA  Prof Olli Yli-Harja, Tampere University of Technology, Finland  Prof Lawrence Young, University of Birmingham, UK  Prof Di-Hua Yu, University of Texas MD Anderson Cancer Center, USA  Prof Yun-Fei Yuan, Sun Yat-Sen University Cancer Center, China  Prof Mu-Sheng Zeng, Sun Yat-Sen University Cancer Center, China  Prof Jian Zhang, Guangxi Medical University, China  Prof Li Zhang, Sun Yat-sen University Cancer Center, China  Prof Ming Zhou, Glickman Urological Institute, USA   Prof Wei-Ping Zhou, University of Michigan, USA      Prof Zhi-Wei Zhou, Sun Yat-sen University Cancer Center, China  Prof Xiao-Feng Zhu, Sun Yat-sen University Cancer Center, China